New targeted drug takes on stomach cancer in Head-to-Head trial
NCT ID NCT04633122
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial compares two oral targeted drugs—ripretinib and sunitinib—in 108 people with advanced gastrointestinal stromal tumors (GIST) whose cancer has worsened on or who cannot tolerate imatinib. The main goal is to see which drug better delays cancer growth. Participants are randomly assigned to receive either ripretinib or sunitinib, and their progress is tracked over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ripretinib (a targeted oral drug) compared to sunitinib (another targeted oral drug)
What this could lead to
If ripretinib works better than sunitinib, it could offer a new treatment option for people with advanced GIST whose cancer has stopped responding to imatinib.
What could go wrong
This is a Phase 2 trial with only 108 participants, so results may not apply to everyone. It is also an open-label study, which can introduce bias. There is no guarantee ripretinib will be better or safer than sunitinib.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMOR (GIST) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
-
Fudan University Cancer Hospital
Shanghai, Shanghai Municipality, China
-
Fudan University, Zhongshan Hospital
Shanghai, Shanghai Municipality, China
-
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
-
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
-
The 4th Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
-
The Affiliated Hospital of Haerbin MedicalUniversity
Harbin, Heilongjiang, China
-
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
-
The Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
-
The Cancer Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
-
The First Affiliated Hospital of Chongqing Medical Universty
Chongqing, Chognqing, China
-
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
-
The General Hospital of Peking University
Beijing, Beijing Municipality, China
-
The sixth Affiliated hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
-
Union Hospital of HUST
Wuhan, Hubei, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China